Latest Period
Q1 2026
Security Snapshot
Ultragenyx Pharmaceutical Inc. - COMMON STOCK (RARE) Institutional Ownership
CUSIP: 90400D108
13F Institutional Holders and Ownership History from Q1 2014 to Q1 2026
Institutions Reporting
292
Shares (Excl. Options)
98,106,328
Price
$20.95
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / COMMON STOCK
- Symbol
- RARE on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 98,106,328
- Total 13F value
- $2,053,504,491
- Portfolio coverage rank
- 0.01%
- Share change
- +3,604,857
- Value change
- +$63,363,219
- Number of holders
- 292
- Shares outstanding
- 98,459,627
- SEC-reported price per share
- $26.30
- Insider filing price
- $26.30
Latest holder snapshot
5 signals
Issuer context
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- RARE - Ultragenyx Pharmaceutical Inc. - COMMON STOCK is tracked under CUSIP 90400D108.
- 292 institutions reported positions in Q1 2026.
- 6 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 285 to 292 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $2,157,034,779 to $2,053,504,491.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 292 institutions filings for Q1 2026.
Security key
90400D108
Latest holder period
Q1 2026
13F holders
292
13D/G owners
6
CIK / CUSIP context first
Open Q1 2026 holders
RARE full holder history
Ultragenyx Pharmaceutical Inc. SEC filings
Ultragenyx Pharmaceutical Inc. company facts
Ultragenyx Pharmaceutical Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 90400D108:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
6
Security
RARE
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| VANGUARD PORTFOLIO MANAGEMENT LLC | 5.5% | $113,343,858 | 5,410,208 | Vanguard Portfolio Management | 31 Mar 2026 | |||
| STATE STREET CORP | 5.1% | $114,840,356 | 5,021,441 | STATE STREET CORPORATION | 31 Mar 2026 | |||
| BlackRock, Inc. | 5.1% | $183,098,959 | 4,820,931 | BlackRock, Inc. | 31 Mar 2025 | |||
| SANDS CAPITAL MANAGEMENT, LLC | 4.7% | $163,238,154 | 4,298,003 | SANDS CAPITAL MANAGEMENT, LLC | 31 Dec 2024 | |||
| FMR LLC | 3.5% | -60% | $77,001,475 | -$106,192,081 | 3,347,890 | -58% | FMR LLC | 31 Dec 2025 |
| WELLINGTON MANAGEMENT GROUP LLP | 2.7% | $93,337,483 | 2,457,543 | Wellington Management Group LLP | 31 Dec 2024 |
As of 31 Mar 2026, 292 institutional investors reported holding 98,106,328 shares of Ultragenyx Pharmaceutical Inc. - COMMON STOCK (RARE). This represents 100% of the company’s total 98,459,627 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
67%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| BlackRock, Inc. | 7.4% | 7,299,598 | +10% | 0% | $152,926,579 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 5.5% | 5,385,992 | 0% | 0.01% | $112,836,532 |
| STATE STREET CORP | 5.1% | 5,021,441 | +17% | 0% | $105,199,189 |
| AQR CAPITAL MANAGEMENT LLC | 4.6% | 4,578,024 | +236% | 0.04% | $95,909,604 |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.3% | 4,189,831 | 0% | 0% | $87,776,959 |
| RTW INVESTMENTS, LP | 3.7% | 3,648,795 | +22% | 0.76% | $76,442,255 |
| SANDS CAPITAL MANAGEMENT, LLC | 3.3% | 3,214,533 | -7.8% | 0.26% | $67,344,466 |
| Sofinnova Investments, Inc. | 3.2% | 3,145,888 | +3677% | 3.3% | $65,906,354 |
| WELLINGTON MANAGEMENT GROUP LLP | 2.7% | 2,640,812 | +7.3% | 0.01% | $55,325,012 |
| Bellevue Group AG | 2.4% | 2,380,000 | +92148% | 1.2% | $49,861,000 |
| Assenagon Asset Management S.A. | 2.3% | 2,257,671 | +1030% | 0.08% | $47,298,207 |
| TWO SIGMA INVESTMENTS, LP | 2.2% | 2,205,820 | +420% | 0.04% | $46,211,929 |
| FRONTIER CAPITAL MANAGEMENT CO LLC | 2.2% | 2,191,182 | +12% | 0.47% | $45,905,260 |
| CITADEL ADVISORS LLC | 2.1% | 2,115,491 | -9.1% | 0.03% | $44,319,536 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.9% | 1,849,391 | +0.61% | 0% | $38,754,433 |
| MILLENNIUM MANAGEMENT LLC | 1.8% | 1,772,184 | +101% | 0.03% | $37,127,255 |
| GW&K Investment Management, LLC | 1.6% | 1,615,426 | +17% | 0.3% | $33,844,000 |
| MORGAN STANLEY | 1.5% | 1,500,527 | -18% | 0% | $31,436,053 |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 1.5% | 1,431,071 | -18% | 0.13% | $29,980,937 |
| VOLORIDGE INVESTMENT MANAGEMENT, LLC | 1.4% | 1,426,834 | +122% | 0.12% | $29,892,172 |
| D. E. Shaw & Co., Inc. | 1.3% | 1,261,018 | +266% | 0.02% | $26,418,327 |
| Rock Springs Capital Management LP | 1.2% | 1,218,773 | -3.8% | 1.5% | $25,533,294 |
| Jones Hill Capital LP | 1.2% | 1,165,557 | 0% | 5.2% | $24,418,419 |
| Candriam S.C.A. | 1.1% | 1,096,182 | +37% | 0.12% | $22,965,013 |
| BANK OF AMERICA CORP /DE/ | 1.1% | 1,046,546 | -14% | 0% | $21,925,127 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
49
Latest
Q1 2026
Rows shown
1-25 of 49
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 98,106,328 | $2,053,504,491 | +$63,363,219 | $20.95 | 292 |
| 2025 Q4 | 93,873,160 | $2,157,034,779 | -$88,987,931 | $23.00 | 285 |
| 2025 Q3 | 95,480,928 | $2,872,333,685 | -$30,390,841 | $30.08 | 301 |
| 2025 Q2 | 94,131,376 | $3,423,160,510 | +$191,188,547 | $36.36 | 307 |
| 2025 Q1 | 88,841,861 | $3,218,915,813 | +$30,616,617 | $36.21 | 297 |
| 2024 Q4 | 87,497,812 | $3,681,153,433 | +$1,949,206 | $42.07 | 309 |
| 2024 Q3 | 86,896,233 | $4,824,969,188 | -$72,319,917 | $55.55 | 299 |
| 2024 Q2 | 88,212,580 | $3,625,598,894 | +$337,028,289 | $41.10 | 273 |
| 2024 Q1 | 79,925,459 | $3,729,060,008 | -$19,184,689 | $46.69 | 268 |
| 2023 Q4 | 80,397,353 | $3,844,802,509 | +$498,492,380 | $47.82 | 236 |
| 2023 Q3 | 70,612,041 | $2,517,056,820 | +$10,459,486 | $35.65 | 219 |
| 2023 Q2 | 69,514,116 | $3,206,303,623 | +$38,331,356 | $46.13 | 239 |
| 2023 Q1 | 68,735,803 | $2,755,924,776 | +$28,159,264 | $40.10 | 227 |
| 2022 Q4 | 68,068,127 | $3,153,029,340 | +$13,205,113 | $46.33 | 225 |
| 2022 Q3 | 67,920,512 | $2,812,302,784 | -$149,070,496 | $41.41 | 223 |
| 2022 Q2 | 67,540,585 | $4,030,154,883 | +$24,063,212 | $59.66 | 210 |
| 2022 Q1 | 67,087,441 | $4,870,684,649 | -$37,258,962 | $72.62 | 227 |
| 2021 Q4 | 67,646,883 | $5,688,385,130 | +$80,515,709 | $84.09 | 224 |
| 2021 Q3 | 66,666,465 | $6,012,124,489 | +$97,920,619 | $90.19 | 217 |
| 2021 Q2 | 65,481,898 | $6,240,143,536 | -$246,149,121 | $95.35 | 235 |
| 2021 Q1 | 67,877,270 | $7,730,039,829 | +$45,641,218 | $113.86 | 244 |
| 2020 Q4 | 67,658,657 | $9,366,525,048 | +$640,902,584 | $138.43 | 247 |
| 2020 Q3 | 63,092,193 | $5,187,430,003 | -$8,503,385 | $82.19 | 199 |
| 2020 Q2 | 63,208,158 | $4,944,359,312 | +$242,670,060 | $78.22 | 185 |
| 2020 Q1 | 60,196,473 | $2,674,187,064 | +$87,973,460 | $44.43 | 166 |